Welcome to our dedicated page for KANE BIOTECH ORD news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on KANE BIOTECH ORD stock.
Kane Biotech Inc. (KNBIF) is a biotechnology company dedicated to researching, developing, and commercializing technologies and products that prevent and eliminate microbial biofilms. With a robust portfolio of intellectual property and products like StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™, the company is at the forefront of biofilm research. Recently, Kane Biotech announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel. The company is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.
Rhea-AI Summary
Kane Biotech Inc. announces its financial results for Q4 and full year 2023, revealing a non-binding offer for its interest in STEM Animal Health. The company received deposits totaling US $1.525 million towards the sale. Q4 saw positive revenue growth with an increase in license and royalty income by 66%, product revenue by 9%, and total revenue by 11%. However, operating expenses surged by 96%, leading to a loss of ($1,611,894) for the quarter. Full year 2023 showed a decrease in license and royalty income by 22% but an increase in product revenue by 25%. Despite a 6% rise in total revenue, the company reported a higher loss of ($5,270,053) for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. extends the exclusivity period for its interest in STEM Animal Health until March 31, 2024. The company has received additional deposits totaling US $900,000 towards the sale price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. to announce Q4 and full year 2023 financial results on March 26, 2024. Conference call to discuss results and business developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kane Biotech Inc. receives the BAM Company of the Year award for its significant achievements in 2023, including FDA clearance, distribution agreements, licensing agreements, and revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. appoints Dr. Robert Huizinga as a director and Executive Chair, focusing on strategic initiatives and partnerships to enhance wound and skin care solutions. Dr. Huizinga's background in Nephrology and successful FDA approval history brings valuable expertise to Kane Biotech.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. announces the introduction of its revyve™ Antimicrobial Wound Gel Spray at the Boswick Burn and Wound Care Symposium. The spray gel, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, has been patented and is designed to simplify application to wounds, reduce infection risk, and minimize pain for patients. The product is pending FDA clearance and is expected to have a significant impact on treating sensitive wounds, particularly burns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
Kane Biotech Inc. announces the presentation of its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium. The gel, featuring thermo-reversible properties, is designed for sensitive wounds such as burns and offers prolonged antimicrobial activity in a moist environment. Dr. Gregory Schultz, Chief Scientific Officer, expresses excitement for the presentation and anticipates a positive reception within the wound care community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. announces a special meeting of its shareholders to consider the election of Dr. Robert Huizinga as an additional director. Dr. Huizinga has an extensive background in the pharmaceutical industry and has been a member of Kane Biotech’s Scientific Advisory Board since 2018.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) corrects the maturity date of its credit facility to March 31, 2024, not March 31, 2023 as previously stated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) announces an agreement with Pivot I Financial Limited Partnership to extend the maturity date of its credit facility, allowing the company to work towards closing a share purchase agreement for its interest in STEM Animal Health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of KANE BIOTECH ORD (KNBIF)?
The current stock price of KANE BIOTECH ORD (KNBIF) is $0.08 as of January 21, 2025.
What is the market cap of KANE BIOTECH ORD (KNBIF)?
The market cap of KANE BIOTECH ORD (KNBIF) is approximately 10.6M.
What is Kane Biotech Inc. known for?
Kane Biotech is recognized for its research, development, and commercialization of technologies and products that prevent and remove microbial biofilms.
What are some of the key products offered by Kane Biotech?
Some of the key products offered by Kane Biotech include StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™.
Where is Kane Biotech listed?
Kane Biotech is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.
What recent achievements has Kane Biotech announced?
Kane Biotech recently announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel.
Who is the President and CEO of Kane Biotech?
The President and CEO of Kane Biotech is Marc Edwards.
What sets Kane Biotech apart in the biotechnology industry?
Kane Biotech stands out for its focus on biofilm research and its innovative portfolio of intellectual property and products.
How can investors participate in Kane Biotech's growth?
Investors can engage with Kane Biotech by trading its shares on the TSX Venture Exchange under the symbol 'KNE' or on the OTCQB Venture Market under the symbol 'KNBIF'.
What recent financial results has Kane Biotech shared?
Kane Biotech announced its fourth quarter and full year 2023 financial results, as well as its first quarter 2024 financial results.
Where can I find more information about Kane Biotech?
For more information about Kane Biotech, visit their website or explore their filings on SEDAR.
What industry does Kane Biotech operate in?
Kane Biotech operates in the biotechnology industry, specifically focusing on technologies and products related to microbial biofilms.
KANE BIOTECH INC ORD